Skip to main content

Agilis Biotherapeutics and Dr. Edwin Weeber Enter Into Worldwide Licensing Agreement For Angelman Syndrome Gene Therapy

“It has been our hope from day one that the pharmaceutical industry would recognize the promise for developing therapeutics for Angelman Syndrome, we are thrilled that Agilis has come forward to invest in this promise and invest in an amazing researcher, which will move us closer to the goals of treatments for this disorder.” ~  Rebecca Burdine Ph.D., Assoc Professor at Princeton University and Chief Science Officer for FAST. Read more about the partnership with Dr. Edwin Weeber and Agilis Biotherapeutics…